About Acadia Pharmaceuticals
We take on some of the toughest challenges in neuroscience and rare disease to deliver innovative and vital solutions to people who need them most.
We are Acadia
From pediatric to geriatric, we work together to advance understanding and care across neurology, psychiatry, long-term care, rare disease, and mental health. We’re bringing new understanding to these disease areas like never before. For our families, friends and neighbors. For the millions of people impacted by neurological and rare disorders who are fighting for their future every day.
Leading Innovative Treatments
We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. We are working with health authorities outside of the U.S. and Canada to seek approvals of our treatment option for people living with Rett syndrome.
Developing Therapies for Unmet Needs
Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis, essential tremor, and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.
Join Our Team
We are seeking individuals with diverse skills, experiences, and backgrounds to join our growing team. Headquartered in San Diego, California, with a presence across Europe, the United States, and Canada, we are building a world-class organization dedicated to improving lives and elevating the standard of care in neuroscience and rare disease.
Partner With Us
Collaboration is key to our success. We are dedicated to partnering with organizations, companies, and individuals to help develop therapies to treat rare diseases and disorders of the central nervous system.
We welcome the opportunity to learn how we can work together. To explore partnering opportunities, please contact Acadia Business Development at [email protected].
